Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease

• Published in: Diabetes research and clinical practice Vol. 94; no. 2; pp. 167 - 171
• Main Authors: Hara, Katsuko, Hirowatari, Yuji, Shimura, Yuko, Takahashi, Hakuo
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.11.2011
• Subjects: Aged; Analysis of Variance; Atherosclerosis; biomarkers; Biomarkers - blood; blood; blood groups; Blood Platelets - metabolism; Cardiovascular Diseases - blood; Cardiovascular Diseases - etiology; Chromatography, High Pressure Liquid; Chronic Disease; Diabetes mellitus; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetic Nephropathies - blood; Diabetic Nephropathies - diagnosis; Diabetic Nephropathies - etiology; Diabetic Nephropathies - physiopathology; Endocrinology & Metabolism; Female; Glomerular Filtration Rate; high performance liquid chromatography; HPLC; Humans; Japan; Kidney - physiopathology; kidney diseases; Male; Middle Aged; noninsulin-dependent diabetes mellitus; patients; people; Platelet; Platelet Activation; renal function; risk; Serotonin; Serotonin - blood; Severity of Illness Index; Up-Regulation; Japan; Platelet; Serotonin; Diabetes mellitus; HPLC; Atherosclerosis

Patients with diabetes mellitus (DM) are prone to atherosclerosis. Atherosclerosis activates platelets; activated platelets release serotonin, and therefore, evaluation of serotonin levels in blood could be a valuable biomarker for future risk of cardiovascular events. Plasma serotonin levels obtain...